The PancChat Podcast is a collaborative effort from Let’s Win Pancreatic Cancer and the Pancreatic Cancer Action Network (PanCAN), inspired by the long-running #PancChat Twitter/X chat.
Hosted by award-winning journalist Alisyn Camerota, each episode features conversations with leading researchers, clinicians, patients, and advocates who are shaping the future of pancreatic cancer care and research. Together, we deliver expert insights, personal journeys, and the latest breakthroughs—bridging the gap between science and lived experience.
Whether you’re a patient, caregiver, healthcare professional, or simply want to learn more, join us to connect, be inspired, and learn how you can help to accelerate progress in the fight against pancreatic cancer.
Up to 95% of pancreatic cancer patients have a KRAS mutation in their tumor. For decades, it was considered impossible to target with a drug. What changed?
To get the latest information, host Alisyn Camerota is joined by Dr. Eileen O'Reilly, medical oncologist and Winthrop Rockefeller Endowed Chair in Medical Oncology at Memorial Sloan Kettering Cancer Center, to unpack what RAS and KRAS actually are, why this gene resisted treatment for so long, and what the recent approval of Rasonque™ (daraxonrasib) means for patients with metastatic pancreatic cancer.
Dr. O'Reilly explains the biology behind RAS signaling, the different mutation types found in pancreatic cancer (including G12D, G12V, and G12R), how the new class of RAS-targeting drugs works, what testing for a RAS mutation involves, and what "RAS wild type" means for the small subset of patients without a detectable mutation. She also shares her perspective on what this breakthrough means for the field after years of limited progress, and where research is headed next.
PancChat is produced in collaboration with Let's Win Pancreatic Cancer (https://letswinpc.org)and PanCAN (https://pancan.org).
PancChat is sponsored by Revolution Medicines.
Resources:
FDA Approves RASONQUE™ (daraxonrasib) (https://pancan.org/news/fda-approves-rasonque-daraxonrasib/) - PanCAN
The FDA Approves Rasonque™ (Daraxonrasib) (https://bit.ly/4gU9OIp) - Let's Win
Daraxonrasib: What To Know About Common Side Effects (https://bit.ly/4iQ354H)
Let's Win Pancreatic Cancer (https://bit.ly/4aTSz8m)
Pancreatic Cancer Action Network (PanCAN) (https://bit.ly/40QANge)
Let's Win Clinical Trial Finder (https://bit.ly/4r0tVYg)
PanCAN Clinical Trial Finder (https://bit.ly/46qzJ6c)
Let's Win Doctor Finder (https://bit.ly/4aPl4DJ)
PanCAN Patient Services (https://bit.ly/4u5bBAc)
8 Sept 2026
Rasonque™: A New Drug for Pancreatic Cancer
The U.S. Food & Drug Administration (FDA) just approved a treatment that doubled survival time for patients with metastatic pancreatic cancer — what does this landmark approval mean for you or a loved one?
To get the latest information, host Alisyn Camerota is joined by Dr. Brian Wolpin, a medical oncologist at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School.
Dr. Wolpin breaks down what the FDA's approval of Rasonque™ (daraxonrasib) means for patients, how the drug works differently from chemotherapy, who's eligible to receive it, what side effects look like and how they're managed, and what's next as researchers explore other types of RAS inhibitors, novel combinations, different stages of disease, and more.
PancChat is produced in collaboration with Let's Win Pancreatic Cancer (https://letswinpc.org) and PanCAN. (https://pancan.org)
Thanks to our sponsor, Revolution Medicines.
Resources:
FDA Approves RASONQUE™ (daraxonrasib) (https://pancan.org/news/fda-approves-rasonque-daraxonrasib/) - PanCAN
The FDA Approves Rasonque™ (Daraxonrasib) (https://bit.ly/4gU9OIp) - Let's Win
Daraxonrasib: What To Know About Common Side Effects (https://bit.ly/4iQ354H)
Let's Win Pancreatic Cancer (https://bit.ly/4aTSz8m)
Pancreatic Cancer Action Network (PanCAN) (https://bit.ly/40QANge)
Let's Win Clinical Trial Finder (https://bit.ly/4r0tVYg)
PanCAN Clinical Trial Finder (https://bit.ly/46qzJ6c)
Let's Win Doctor Finder (https://bit.ly/4aPl4DJ)
PanCAN Patient Services (https://bit.ly/4u5bBAc)
25 Aug 2026
Managing Diabetes During Treatment
Diabetes and pancreatic cancer often go hand in hand. Between 30 to 50% of patients have diabetes or prediabetes at diagnosis, and another 40% develop it during treatment.
To get the latest information, host Alisyn Camerota is joined by endocrinologist and Director of the Duke Onco-Endocrinology Program at the Duke Center for Cancer Immunotherapy, Dr. Afreen Shariff, an Associate Director for the Cancer Therapy Toxicity Program and a member of the faculty in the Division of Endocrinology, Diabetes, and Metabolism at Duke University School of Medicine.
In this episode, Dr. Shariff discusses managing pancreatic cancer and diabetes, and how surgery, chemotherapy, and radiation can all affect blood sugar as a direct, on-target effect of treatment. She emphasizes working with an endocrinologist and oncologist to help control diabetes during and after treatment.
Her advice: get a clear diagnosis, know your numbers, and don't hesitate to bring up blood sugar concerns with your oncology team.
PancChat is produced in collaboration with Let's Win Pancreatic Cancer and PanCAN.
This episode is sponsored by Revolution Medicines.
For more information, visit letswinpc.org (https://letswinpc.org) and pancan.org (https://pancan.org).
RESOURCES:
Let's Win's Diabetes Section (https://bit.ly/4wFjfkF)
PancCAN Diabetes and Pancreatic Cancer (https://bit.ly/4xY3I0r)
PanCAN Patient Services (https://bit.ly/4u5bBAc)
Let's Win Doctor Finder (https://bit.ly/4aPl4DJ)
Let's Win Clinical Trial Finder (https://bit.ly/4r0tVYg)
PanCAN Clinical Trial Finder (https://bit.ly/4r0tVYg)
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
YouTube views
274,052
Score snapshot 15 Sept 2025
Apple Podcasts (US)
5.0 / 5
7 ratings
Spotify
5.0 / 5
1 ratings
Podcast Authority Score: 54 / 100
A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.
Quality
62
Social presence
0
YouTube
86
Engagement
32
Contact PancChat Podcast with Alisyn Camerota
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
